Demand for Blood Glucose Monitoring Devices in USA

Demand for Blood Glucose Monitoring Devices in USA 2025 to 2035

Demand for blood glucose monitoring devices in the USA is projected to grow from USD 4.21 billion in 2025 to approximately USD 9.12 billion by 2035, recording an absolute increase of USD 4.91 billion over the forecast period. This translates into a total growth of 116.6%, with demand forecast to expand at a compound annual growth rate (CAGR) of 8.0% between 2025 and 2035.

Quick Stats for USA Blood Glucose Monitoring Devices Industry

• USA Blood Glucose Monitoring Devices Sales Value (2025): USD 4.21 billion
• USA Blood Glucose Monitoring Devices Forecast Value (2035): USD 9.12 billion
• USA Blood Glucose Monitoring Devices Forecast CAGR: 8.0%
• Leading Product Type in USA Blood Glucose Monitoring Devices Industry: Self-Monitoring Blood Glucose (SMBG) Devices (62.40%)
• Key Growth Regions in USA Blood Glucose Monitoring Devices Industry: West, Northeast, South, Midwest
• Regional Leadership: West holds the leading position in demand
• Key Players in USA Blood Glucose Monitoring Devices Industry: Abbott Laboratories, Medtronic Public Limited Company, F. Hoffmann-La Roche Limited, Ascensia Diabetes Care Holdings AG, Dexcom Incorporated, Sanofi, Novo Nordisk A/S, Insulet Corporation, Ypsomed Holding AG, Glysens Incorporated

The overall demand size is expected to grow by more than 2.1 times during the same period, supported by increasing diabetes prevalence and aging population demographics, growing adoption of continuous glucose monitoring systems and connected health technologies, expanding insurance reimbursement coverage for advanced monitoring devices, and comprehensive diabetes management programs throughout the USA.

The self-monitoring blood glucose (SMBG) devices segment is projected to account for 62.40% of blood glucose monitoring devices demand in 2025. SMBG device applications are widely used in the USA for home care settings, clinical practice facilities, and hospital operations where traditional glucose measurement capabilities, cost-effectiveness characteristics, and proven accuracy benefits remain essential for daily monitoring routines and diabetes management optimization.

The hospitals segment is expected to represent 39.70% of blood glucose monitoring devices demand in 2025. Hospital applications are fundamental to the industry because they provide the clinical oversight, professional monitoring, and comprehensive care required for acute diabetes management and specialized medical applications.

Between 2020 and 2025, blood glucose monitoring devices demand in the USA experienced steady expansion, driven by rising diabetes incidence following demographic changes and growing recognition of continuous monitoring benefits for glycemic control enhancement and complication prevention. The sector developed as healthcare practitioners and diabetes care centers, especially in major metropolitan areas, recognized the need for reliable glucose monitoring systems and effective measurement solutions to achieve optimal patient outcomes while meeting clinical standards and regulatory requirements. Healthcare companies and device manufacturers began emphasizing FDA approval processes and clinical validation to maintain competitive advantages and operational viability.

Between 2025 and 2030, demand for blood glucose monitoring devices in the USA is projected to expand from USD 4.21 billion to USD 6.38 billion, resulting in a value increase of USD 2.17 billion, which represents 44.2% of the total forecast growth for the decade. This phase of growth will be shaped by accelerating continuous glucose monitoring adoption campaigns, rising digital health platform integration investment, and growing regulatory requirements for evidence-based diabetes monitoring systems across USA regions, particularly in areas where healthcare infrastructure and chronic disease management initiatives are accelerating blood glucose monitoring devices adoption. Increasing integration of smartphone connectivity technology in monitoring systems and growing adoption of remote patient monitoring platforms continue to drive demand.

Healthcare providers and device companies are expanding their product capabilities to address the growing complexity of modern diabetes management requirements and clinical standards, with USA operations leading investments in sensor accuracy enhancement methods and efficient data integration systems.

From 2030 to 2035, demand is forecast to grow from USD 6.38 billion to USD 9.12 billion, adding another USD 2.74 billion, which constitutes 55.8% of the overall ten-year expansion. This period is expected to be characterized by expansion of advanced continuous monitoring applications, development of enhanced artificial intelligence-driven glucose prediction capabilities, and implementation of comprehensive automated insulin delivery technology programs across different patient and healthcare sectors. The growing adoption of integrated diabetes management systems and enhanced connectivity optimization platforms, particularly in major healthcare centers and clinical practice operations, will drive demand for more sophisticated monitoring solutions and validated measurement systems.

USA Blood Glucose Monitoring Devices Industry Key Takeaways

Metric	Value
USA Blood Glucose Monitoring Devices Sales Value (2025)	USD 4.21 billion
USA Blood Glucose Monitoring Devices Forecast Value (2035)	USD 9.12 billion
USA Blood Glucose Monitoring Devices Forecast CAGR (2025-2035)	8.0%

Why is the USA Blood Glucose Monitoring Devices Industry Growing?

The USA blood glucose monitoring devices industry is driven by a surge in the broader diabetes care sector. A considerable growth in demand for both advanced continuous monitoring solutions and traditional glucose measurement products has created a larger base of healthcare providers, diabetes specialists, and patients requiring reliable blood glucose monitoring devices products. Changing healthcare patterns mandate the use of efficient evidence-based systems for optimal diabetes management performance and glycemic control optimization. This compliance-driven demand establishes a consistent, clinically-based foundation. As new practitioners enter the diabetes care segment and existing healthcare practices are modernized, the need for standard-issue and specialized blood glucose monitoring devices products forms a stable foundation for the industry's growth, ensuring a continuous stream of customers driven by medical necessity and clinical compliance.

Technological innovation serves as a powerful secondary engine for this growth. Modern blood glucose monitoring devices systems are no longer just basic glucometers; they are advanced measurement solutions. The rapid adoption of specialized continuous glucose monitoring technologies has become a major selling point, significantly reducing testing complexity and enhancing measurement reliability. Beyond traditional options, manufacturers are integrating advanced connectivity systems for seamless incorporation with digitally conscious healthcare approaches, and compatibility with various clinical requirements. These features, coupled with improvements in sensor accuracy, device convenience, and measurement quality, are compelling both healthcare and patient operators to upgrade from basic meters, driving a cycle of replacement and premiumization within the industry.

An increasing emphasis on diabetes management efficiency, particularly exploration of advanced monitoring technologies, is pushing demand for higher-quality, more diverse blood glucose monitoring devices varieties. The segment has also expanded beyond traditional healthcare channels, with growing interest from the home care sector, telemedicine applications, and even remote monitoring units. This diversification, combined with the rise of specialized platforms that improve accessibility for all patients, ensures that manufacturers can reach a wider audience than ever before. This confluence of efficiency, innovation, and accessibility creates a fertile ground for continued industry expansion.

Segmental Analysis

The industry is segmented by product type, end use, and region. By product type, the industry is divided into self-monitoring blood glucose (SMBG) devices and continuous glucose monitoring (CGM) devices. In terms of end use, the industry is segmented into hospitals, home care, and diagnostic centers, with self-monitoring blood glucose devices representing a key growth and innovation hub for monitoring technologies. Regionally, the industry is divided into West, Northeast, South, and Midwest.

Why Do Self-Monitoring Blood Glucose (SMBG) Devices Account for High Share of 62.40%?

The self-monitoring blood glucose (SMBG) devices segment is projected to account for 62.40% of blood glucose monitoring devices demand in 2025, making it the leading product type across the sector. This dominance reflects the affordability requirements and patient accessibility needs of glucose monitoring systems for existing healthcare providers and home care applications where measurement efficiency is optimized through proven reliability characteristics and integrated testing architecture.

In the USA, where substantial healthcare infrastructure requires monitoring integration without complete system redesign, SMBG blood glucose monitoring devices solutions provide practical pathways for diabetes management while maintaining patient preferences. Continuous innovations are improving accuracy optimization, cost preservation, and versatility parameters, enabling healthcare operators to achieve high performance standards while maximizing patient satisfaction.

• Traditional glucose measurement and existing healthcare system integration make SMBG devices the preferred product type for enhancing healthcare providers and patient operations.
• Clinical validation and performance track records are enhancing patient confidence and product viability across large-scale adoption initiatives.

Why Do Hospitals Hold High Share of 39.70%?

Hospital are expected to represent 39.70% of blood glucose monitoring devices demand in 2025, reflecting the critical role of clinical settings requiring comprehensive monitoring solutions. Hospital operations including inpatient projects, acute care facilities, and emergency systems generate consistent demand for blood glucose monitoring devices that support efficient clinical utilization and care optimization.

Blood glucose monitoring devices systems are widely adopted for hospital facilities due to significant measurement accuracy benefits and enhanced clinical capabilities. Their reliable, high-performance operation provides effective, cost-efficient monitoring solutions, enhancing operational independence for healthcare users.

• Clinical requirements and hospital operations drive substantial demand for specialized blood glucose monitoring devices designed for healthcare applications.
• Accuracy optimization and monitoring efficiency demands create consistent clinical requirements across major USA regions and healthcare facilities.

What are the Drivers, Restraints, and Key Trends in the USA Blood Glucose Monitoring Devices Industry?

The demand for blood glucose monitoring devices in the USA is advancing steadily due to increasing diabetes requirements and growing recognition of advanced monitoring necessity for glycemic protection, with the West region serving as a key driver of innovation and healthcare modernization. The sector faces challenges including initial cost considerations, insurance limitations with certain applications, and ongoing concerns regarding device constraints and clinical validation requirements.

Growth in Healthcare Infrastructure Development and Diabetes Management Programs

The enhancement of clinical standards, gaining particular significance through diabetes trends and chronic disease management campaigns, is enabling blood glucose monitoring devices providers to achieve differentiation without prohibitive production costs, providing predictable demand patterns through patient requirements and practitioner preferences. Enhanced clinical standards offering substantial opportunities for blood glucose monitoring devices systems and integrated applications provide foundational dynamics while allowing providers to secure healthcare provider agreements and distribution partnerships.

Incorporation of Advanced Continuous Monitoring Capabilities and Evidence-Based Device Systems

Modern blood glucose monitoring devices providers and healthcare operators are establishing advanced manufacturing networks and centralized production facilities that improve manufacturing efficiency through process standardization and quality analytics. Integration of continuous monitoring enhancement systems, evidence-based validation technology, and coordinated quality management enables more efficient production operations across multiple manufacturing regions.

Creation of Digital Health Systems and Enhanced Patient Targeting Methods

The expansion of digital health systems and patient segmentation is driving development of specialized blood glucose monitoring devices systems with enhanced monitoring profiles, improved connectivity characteristics, and optimized clinical attributes that address current limitations and expand device applications beyond traditional glucometers. These specialized systems require sophisticated monitoring capabilities and performance expertise that exceed traditional manufacturing requirements, creating specialized demand segments with differentiated product propositions. Producers are investing in patient targeting and clinical optimization to serve emerging healthcare applications while supporting innovation in performance development and patient engagement.

Analysis of USA Blood Glucose Monitoring Devices Industry by Key Region

Region	CAGR (2025-2035)
West	8.30%
Northeast	8.10%
South	7.90%
Midwest	7.70%

The USA blood glucose monitoring devices demand is witnessing steady growth, supported by rising diabetes requirements, expanding healthcare center initiatives, and the deployment of advanced monitoring technologies across regions. West leads the nation with an 8.30% CAGR, reflecting a strong healthcare base, substantial diabetes care development, and established clinical innovation facilities.

Why Does the West Region Dominate Blood Glucose Monitoring Devices Demand?

Demand for blood glucose monitoring devices in West is projected to exhibit strong growth with a CAGR of 8.30% through 2035, driven by a strong healthcare base, substantial diabetes care development creating advanced monitoring opportunities, and a concentration of innovation advancement across California, Oregon, Washington, Nevada, and surrounding states.

Advanced diabetes programs and healthcare optimization initiatives are expanding blood glucose monitoring devices adoption among manufacturers, healthcare centers, and clinical suppliers pursuing patient optimization, care development, and specialized monitoring projects throughout major urban hubs and healthcare corridors.

• Healthcare base and diabetes care infrastructure capabilities are requiring comprehensive monitoring strategies and glucose measurement solutions, driving demand for blood glucose monitoring devices systems with demonstrated clinical enhancement performance capabilities and permanent measurement assurance throughout diverse healthcare operations.
• Diabetes care development and monitoring concentration are generating substantial blood glucose monitoring devices demand across healthcare companies, manufacturers, and clinical suppliers serving patient applications and care requirements.

Why Does the Northeast Region Demonstrate Strong Growth?

Demand for blood glucose monitoring devices in Northeast is projected to grow with a CAGR of 8.10% through 2035, supported by established healthcare presence, comprehensive diabetes care development, and strong manufacturing facilities across New York, Pennsylvania, Massachusetts, New Jersey, and surrounding states.

Established healthcare presence and manufacturing leadership are supporting blood glucose monitoring devices adoption throughout manufacturer facilities, clinical operations, and monitoring distribution centers serving care enhancement and diabetes applications.

• Strong healthcare ecosystem and manufacturing networks are enabling blood glucose monitoring devices integration across clinical producers, manufacturers, and device suppliers pursuing advanced care development and diabetes programs.
• Premium diabetes care capabilities and healthcare excellence are driving blood glucose monitoring devices demand among leading manufacturer corporations, clinical centers, and specialized healthcare firms focused on performance enhancement, monitoring optimization, and manufacturing development targeting care applications and advanced patient operations.

Why Does the South Region Show Consistent Demand?

Demand for blood glucose monitoring devices in South is forecast to advance with a CAGR of 7.90% through 2035, driven by expanding healthcare capabilities, growing diabetes care investment, and increasing clinical consciousness across Texas, Florida, Georgia, North Carolina, and surrounding states.

Rising healthcare sector development and manufacturing partnerships are supporting blood glucose monitoring devices integration across device producers, manufacturer facilities, and clinical distributors pursuing care enhancement, patient expansion, and diabetes initiatives throughout expanding monitoring regions and urban centers.

• Growing healthcare infrastructure and diabetes care investment are creating opportunities for blood glucose monitoring devices adoption across emerging clinical hubs, manufacturer facilities, and device distribution centers in major metropolitan areas and healthcare corridors.
• Patient expansion and clinical growth are driving blood glucose monitoring devices demand among healthcare operators seeking enhanced performance capabilities and participation in advanced monitoring programs.

Why Does the Midwest Region Depict Consistent Growth?

Demand for blood glucose monitoring devices in Midwest is expected to expand with a CAGR of 7.70% through 2035, supported by manufacturing capabilities, healthcare infrastructure development, and growing manufacturer efficiency presence across Illinois, Ohio, Wisconsin, Michigan, and surrounding states.

Healthcare expertise and production capabilities are driving blood glucose monitoring devices demand among patient producers, clinical suppliers, and manufacturing companies serving device production and diabetes applications.

• Growing manufacturing development and healthcare investment are supporting blood glucose monitoring devices adoption across emerging production hubs, patient facilities, and manufacturer centers pursuing performance enhancement and monitoring programs.
• Expanding healthcare infrastructure and manufacturing integration are creating opportunities for blood glucose monitoring devices utilization across clinical suppliers, patient production facilities, and manufacturer operations seeking diabetes device production, clinical support, and manufacturing capabilities throughout major healthcare regions and emerging manufacturer patient centers.

Competitive Landscape of USA Blood Glucose Monitoring Devices Industry

USA blood glucose monitoring devices demand is defined by competition among established healthcare corporations, specialized device companies, and integrated clinical producers, with major manufacturer operators maintaining significant influence through production resources and manufacturing capabilities. Companies are investing in device advancement, connectivity optimization, clinical acceptance technologies, and comprehensive performance services to deliver effective, reliable, and efficient diabetes solutions across USA patient and manufacturer applications.

Abbott Laboratories dominates with a 19.20% share, offering comprehensive glucose monitoring solutions including advanced continuous monitoring systems, performance enhancement technologies, and distribution services with a focus on patient applications, clinical consistency, and connectivity optimization across USA operations. The company continues investing in monitoring programs, distribution strategies, and blood glucose monitoring devices innovation while expanding operational presence and advanced manufacturer applications.

Medtronic Public Limited Company provides specialized integrated solutions with emphasis on performance development and manufacturing excellence. Dexcom Incorporated focuses on premium continuous monitoring development and patient applications. F. Hoffmann-La Roche Limited emphasizes diabetes development and specialized manufacturer equipment production. Ascensia Diabetes Care Holdings AG offers traditional device technology solutions and professional performance support. Sanofi specializes in diabetes care development and distribution programs.

USA Blood Glucose Monitoring Devices Industry - Stakeholder Contribution Framework

The USA blood glucose monitoring devices industry is a critical backbone for national diabetes optimization, supporting healthcare installations, manufacturer infrastructure, and patient applications. With a projected demand value driven by diabetes development, patient equipment adoption cycles, and monitoring technology advancement, the sector's resilience depends on collaborative engagement among government agencies, manufacturer operators, device companies, and investors to modernize infrastructure, enhance efficiency, and secure supply chains.

How Governments Could Accelerate Infrastructure Modernization and Industry Competitiveness?

• Federal Healthcare Infrastructure Grants: Expand funding through the Department of Health and Human Services and Food and Drug Administration for R&D into advanced monitoring materials, efficiency-enhanced technologies, and measurement systems to enhance performance and longevity.
• Tax Incentives for Equipment Installation: Offer investment tax credits for operators replacing conventional glucometers with high-efficiency blood glucose monitoring devices, clinical systems, or smart diabetes systems that reduce maintenance consumption and operational costs.
• Domestic Manufacturing and Production Support: Implement policies and strategic reserves for domestic monitoring production, ensuring a resilient supply of raw materials and mitigating import dependency and price volatility.
• Standardized Diabetes and Certification Policies: Introduce unified federal standards for blood glucose monitoring devices manufacturing, performance testing, and installation inspection to streamline regulatory approval and boost interoperability.
• Permitting Process Reform: Expedite environmental reviews and permitting for critical monitoring projects that enhance national healthcare grid efficiency and diabetes capacity.
• Digital Monitoring Mandates: Promote the deployment of smart sensors, wireless connectivity, and remote monitoring technologies as part of device management protocols.

How Industry Bodies & Associations Could Strengthen Sector Coordination and Technical Leadership?

• Unified Material and Diabetes Standards: Develop consensus-based benchmarks for monitoring grades, diabetes ratings, and performance standards to ensure interoperability and system-wide efficiency.
• Workforce Development Programs: Create certification pathways for monitoring technicians, diabetes installers, and healthcare engineers to address the skilled labor shortage and ensure quality installation.
• Collaborative R&D Consortia: Establish joint programs linking operators, manufacturers, and research institutions to drive innovation in clinical-detection technologies, advanced materials, and measurement systems.
• Performance Data Repositories: Build centralized industry databases for performance incident data, efficiency rates, and material performance to inform better design and maintenance standards.
• Public Outreach and Awareness: Promote the role of modern monitoring infrastructure in diabetes reliability, economic growth, and patient protection through coordinated industry campaigns.

How Blood Glucose Monitoring Devices Manufacturers & Technology Suppliers Could Capture Value and Drive Innovation?

• Advanced Monitoring Manufacturing: Invest in production technologies for high-grade clinical systems, efficiency-enhanced containers, and smart diabetes solutions for demanding applications.
• Diabetes Monitoring System Integration: Develop integrated monitoring platforms combining smart sensor data, wireless monitoring, and performance analytics for predictive maintenance.
• Supply Chain Digitalization: Implement digital traceability from component sourcing to final installation, using blockchain or QR codes to ensure material provenance and quality compliance.
• Partnership with Research Institutions: Collaborate with national labs on next-generation materials, such as advanced monitoring technologies and composite diabetes systems for high-performance applications.
• Patient Optimization: Introduce automated manufacturing systems, advanced clinical applications, and modular container fabrication to lower manufacturing costs and improve throughput.

How Manufacturer Operators & Infrastructure Companies Could Optimize Patient Efficiency and Demand Expansion?

• Digital Asset Integration: Create digital replicas of monitoring assets integrated with real-time sensor data to optimize performance, predict maintenance, and simulate efficiency scenarios.
• Scale-up of High-Value Applications: Focus on monitoring specifications for patient developments, high-efficiency diabetes projects, and healthcare transportation networks.
• Collaborative Supply Ecosystems: Develop long-term contracts with container manufacturers and technology suppliers to ensure consistent quality and secure capacity during expansion cycles.
• Pilot-to-Field Deployment Transition: Use phased testing for new monitoring technologies, such as advanced clinical systems for manufacturer service, before full-scale field deployment.
• Lifecycle Cost Optimization: Invest in premium monitoring materials and technologies during installation to reduce long-term maintenance and operational expenses.

How Patient & Service Companies Could Lead Cross-Sector Integration?

• Manufacturer and Utility Integration: Deploy advanced monitoring and optimization technologies for aging distribution networks in urban and patient areas.
• Facility and Asset Enhancement: Incorporate real-time diabetes management platforms that combine performance data with efficiency assessment for a comprehensive view of asset health.
• Distribution and Grid System Management: Apply advanced efficiency-based methodologies to prioritize maintenance on vast and often complex monitoring networks.
• Regional Testing and Validation Hubs: Create regional facilities to test and validate new monitoring tools, efficiency technologies, and device systems under simulated field conditions.
• Monitoring Life Extension Initiatives: Reuse and upgrade container segments for enhanced efficiency services and optimize rehabilitation programs through advanced technology and smart management systems.

How Engineering & Construction Firms Could Unlock Application Innovation and Demand Access?

• Design and Material Expansion: Develop customized monitoring solutions for challenging environments, including urban conditions, weather zones, and high-efficiency applications.
• Modular Diabetes Applications: Integrate prefabricated and pre-optimized monitoring systems into facility design to reduce field installation time and costs.
• Advanced Project Delivery Systems: Offer integrated EPC (Engineering, Procurement, and Construction) platforms that include digital as-built handover with all monitoring material records.
• Design for Patient Services: Partner with operators to provide co-engineered monitoring systems optimized for constructability, operability, and long-term efficiency.
• Digital Platform Development: Launch project management platforms for standardized container components, procurement tracking, and quality assurance documentation.

How Investors and Financial Enablers Could Unlock Growth and Technology Scalability?

• Venture Capital for Technology Startups: Support early-stage companies developing novel monitoring systems, efficiency-based detection, and AI-driven diabetes software.
• Infrastructure and Modernization Financing: Provide capital for monitoring replacement programs, manufacturer facility upgrades, and digital control system installations.
• Public-Private Investment Platforms: Create co-financed funds for pilot projects demonstrating patient efficiency or infrastructure transportation in enhanced or new-built monitoring systems.
• Strategic Consolidation Funding: Back mergers and acquisitions that consolidate fragmented monitoring technology, service, or manufacturing companies to achieve scale and geographic reach.
• Performance-Linked Financing Models: Tie loan terms and investor returns to key performance indicators like reduced diabetes consumption, improved efficiency records, and enhanced patient performance.
• Healthcare Transition Financing Programs: Channel innovation-oriented funds into monitoring systems dedicated to patient efficiency, healthcare development, and diabetes efficiency networks.

Key Players in USA Blood Glucose Monitoring Devices Industry

• Abbott Laboratories
• Medtronic Public Limited Company
• F. Hoffmann-La Roche Limited
• Ascensia Diabetes Care Holdings AG
• Dexcom Incorporated
• Sanofi
• Novo Nordisk A/S
• Insulet Corporation
• Ypsomed Holding AG
• Glysens Incorporated

Scope of the Report

Item	Value
Quantitative Units	USD 9.12 billion
Product Type	Self-Monitoring Blood Glucose (SMBG) Devices, Continuous Glucose Monitoring (CGM) Devices
End Use	Hospitals, Home Care, Diagnostic Centers
Regions Covered	West, Northeast, South, Midwest
Key Companies Profiled	Abbott Laboratories, Medtronic Public Limited Company, F. Hoffmann-La Roche Limited, Ascensia Diabetes Care Holdings AG, Dexcom Incorporated, Sanofi, Novo Nordisk A/S, Insulet Corporation, Ypsomed Holding AG, Glysens Incorporated
Additional Attributes	Sales by product type and end use segment, regional demand trends across West, Northeast, South, and Midwest, competitive landscape with established healthcare corporations and device suppliers, manufacturer facility preferences for SMBG versus CGM equipment, integration with healthcare centers and advanced diabetes optimization policies particularly advanced in West region

USA Blood Glucose Monitoring Devices Industry by Segments

• Product Type:

  • Self-Monitoring Blood Glucose (SMBG) Devices
  • Continuous Glucose Monitoring (CGM) Devices

• End Use:

  • Hospitals
  • Home Care
  • Diagnostic Centers

• Region:

  • West
  • Northeast
  • South
  • Midwest